Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 2 (February)

1. Diabetes mellitus and breast cancer.
   Lancet Oncol, 6(2): 103-11. [Abstract] [Full-text]
2. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells.
   J Pineal Res, 38(2): 136-42. [Abstract] [Full-text]
3. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination.
   Scand J Immunol, 61(2): 147-56. [Abstract] [Full-text]
4. Accuracy of sonographically guided 14-gauge core-needle biopsy: results of 715 consecutive breast biopsies with at least two-year follow-up of benign lesions.
   J Clin Ultrasound, 33(2): 47-52. [Abstract] [Full-text]
5. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution.
   Cancer, 103(3): 492-500. [Abstract] [Full-text]
6. Predicting psychological morbidity in Chinese women after surgery for breast carcinoma.
   Cancer, 103(3): 637-46. [Abstract] [Full-text]
7. Mammographic screening reduces risk of breast carcinoma recurrence.
   Cancer, 103(3): 474-82. [Abstract] [Full-text]
8. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance.
   Cancer, 103(3): 451-61. [Abstract] [Full-text]
9. The impact of socioeconomic status and race on trial participation for older women with breast cancer.
   Cancer, 103(3): 483-91. [Abstract] [Full-text]
10. Short-term, medium-term, long-term, and lifetime risks of developing and dying of breast carcinoma in a Westernized Chinese population: Evidence from Hong Kong between 1976 and 2000.
    Cancer, 103(3): 501-8. [Abstract] [Full-text]
11. Hormonal regulation of the Grb14 signal modulator and its role in cell cycle progression of MCF-7 human breast cancer cells.
    J Cell Physiol, 203(1): 85-93. [Abstract] [Full-text]
12. Moderate alcohol consumption and levels of antioxidant vitamins and isoprostanes in postmenopausal women.
    Eur J Clin Nutr, 59(2): 161-8. [Abstract] [Full-text]
13. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
    J Natl Cancer Inst, 97(3): 188-94. [Abstract] [Full-text]
14. Antimitotic activity and reversal of breast cancer resistance protein-mediated drug resistance by stilbenoids from Bletilla striata.
    Bioorg Med Chem Lett, 15(4): 1051-4. [Abstract] [Full-text]
15. Imaging anisotropic and viscous properties of breast tissue by magnetic resonance-elastography.
    Magn Reson Med, 53(2): 372-87. [Abstract] [Full-text]
16. Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator.
    Proc Natl Acad Sci U S A, 102(5): 1339-44. [Abstract] [Full-text]
17. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo.
    Proc Natl Acad Sci U S A, 102(5): 1454-9. [Abstract] [Full-text]
18. Diabetic fibrous mastopathy: sonographic-pathologic correlation.
    J Clin Ultrasound, 33(1): 34-7. [Abstract] [Full-text]
19. Decorin prevents metastatic spreading of breast cancer.
    Oncogene, 24(6): 1104-10. [Abstract] [Full-text]
20. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays.
    J Pathol, 205(3): 388-96. [Abstract] [Full-text]
21. Breast cancer in women with HIV/AIDS: report of five cases with a review of the literature.
    J Surg Oncol, 89(1): 23-7. [Abstract] [Full-text]
22. Usefulness of a solid-state gamma camera for sentinel node identification in patients with breast cancer.
    J Surg Oncol, 89(1): 12-7. [Abstract] [Full-text]
23. Multiplexed wavelet transform technique for detection of microcalcification in digitized mammograms.
    J Digit Imaging, 17(4): 285-91. [Abstract] [Full-text]
24. cDNA expression profiling reveals elevated gene expression in cell clusters overlying focally disrupted myoepithelial cell layers: implications for breast tumor invasion.
    Breast Cancer Res Treat, 89(2): 199-208. [Abstract] [Full-text]
25. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory.
    Breast Cancer Res Treat, 89(2): 187-97. [Abstract] [Full-text]
26. Automatic ultrasound segmentation and morphology based diagnosis of solid breast tumors.
    Breast Cancer Res Treat, 89(2): 179-85. [Abstract] [Full-text]
27. Hazard rates of recurrence following diagnosis of primary breast cancer.
    Breast Cancer Res Treat, 89(2): 173-8. [Abstract] [Full-text]
28. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.
    Breast Cancer Res Treat, 89(2): 165-72. [Abstract] [Full-text]
29. The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology.
    Breast Cancer Res Treat, 89(2): 159-63. [Abstract] [Full-text]
30. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry.
    Breast Cancer Res Treat, 89(2): 149-57. [Abstract] [Full-text]
31. Breast hamartoma: a case report.
    Breast Cancer Res Treat, 89(2): 145-7. [Abstract] [Full-text]
32. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
    Breast Cancer Res Treat, 89(2): 135-43. [Abstract] [Full-text]
33. Ultrasound criteria for ductal invasive breast cancer are modified by age, tumor size, and axillary lymph node status.
    Breast Cancer Res Treat, 89(2): 127-33. [Abstract] [Full-text]
34. Usefulness of three-dimensional multidetector-row CT images for preoperative evaluation of tumor extension in primary breast cancer patients.
    Breast Cancer Res Treat, 89(2): 119-25. [Abstract] [Full-text]
35. Breast cancer screening barriers and mammography completion in older minority women.
    Breast Cancer Res Treat, 89(2): 111-8. [Abstract] [Full-text]
36. A comparison of record linkage yield for health research using different variable sets.
    Breast Cancer Res Treat, 89(2): 107-10. [Abstract] [Full-text]
37. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status.
    Breast Cancer Res Treat, 89(2): 99-105. [Abstract] [Full-text]
38. Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab.
    Onkologie, 28(2): 95-7. [Abstract] [Full-text]
39. Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer.
    Am J Epidemiol, 161(4): 330-7. [Abstract] [Full-text]
40. Differential effects of 16alpha-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells.
    J Mol Endocrinol, 34(1): 91-105. [Abstract] [Full-text]
41. Mechanism of transcriptional regulation of LRP16 gene expression by 17-beta estradiol in MCF-7 human breast cancer cells.
    J Mol Endocrinol, 34(1): 77-89. [Abstract] [Full-text]
42. Integrative analysis of gene expression patterns predicts specific modulations of defined cell functions by estrogen and tamoxifen in MCF7 breast cancer cells.
    J Mol Endocrinol, 34(1): 61-75. [Abstract] [Full-text]
43. Computerized scheme for assessing ultrasonographic features of breast masses.
    Acad Radiol, 12(1): 58-66. [Abstract] [Full-text]
44. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.
    Nucl Med Biol, 32(1): 51-8. [Abstract] [Full-text]
45. Glycerophosphoinositols inhibit the ability of tumour cells to invade the extracellular matrix.
    Eur J Cancer, 41(3): 470-6. [Abstract] [Full-text]
46. Increased incidence of stroke in women with breast cancer.
    Eur J Cancer, 41(3): 423-9. [Abstract] [Full-text]
47. A survey of breast cancer awareness and knowledge in a Western population: lots of light but little illumination.
    Eur J Cancer, 41(3): 393-7. [Abstract] [Full-text]
48. Breast-conserving surgery and radiotherapy: a possible treatment for lobular carcinoma in situ?
    Eur J Cancer, 41(3): 380-5. [Abstract] [Full-text]
49. The choice of systemic adjuvant therapy in receptor-positive early breast cancer.
    Eur J Cancer, 41(3): 357-64. [Abstract] [Full-text]
50. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    Eur J Cancer, 41(3): 346-56. [Abstract] [Full-text]
51. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.
    Onkologie, 28(2): 81-5. [Abstract] [Full-text]
52. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
    Biochem J, 386: 119-25. [Abstract] [Full-text]
53. Long-term breast cancer survivors' use of complementary therapies: perceived impact on recovery and prevention of recurrence.
    Integr Cancer Ther, 4(1): 14-20. [Abstract] [Full-text]
54. Intravascular large B-cell lymphoma of the breast.
    Breast, 14(1): 75-8. [Abstract] [Full-text]
55. ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual.
    Breast, 14(1): 71-4. [Abstract] [Full-text]
56. Bowen's disease of the nipple-a new method of treatment.
    Breast, 14(1): 65-7. [Abstract] [Full-text]
57. Endoscopic quadrantectomy for breast cancer with sentinel lymph node navigation via a small axillary incision.
    Breast, 14(1): 57-60. [Abstract] [Full-text]
58. Haematological cancers in the breast and axilla: a drop in an ocean of breast malignancy.
    Breast, 14(1): 51-6. [Abstract] [Full-text]
59. Intra-operative assessment of excision margins using breast imprint and scrape cytology.
    Breast, 14(1): 42-50. [Abstract] [Full-text]
60. One-year morbidity after sentinel node biopsy and breast surgery.
    Breast, 14(1): 28-36. [Abstract] [Full-text]
61. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions.
    Breast, 14(1): 22-7. [Abstract] [Full-text]
62. The effect of immediate breast reconstruction on adjuvant chemotherapy.
    Breast, 14(1): 18-21. [Abstract] [Full-text]
63. Surgical caseload and outcomes for women with invasive breast cancer treated in Western Australia.
    Breast, 14(1): 11-7. [Abstract] [Full-text]
64. 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity?
    Breast, 14(1): 3-10. [Abstract] [Full-text]
65. Retinoids and human breast cancer: in vivo effects of an antagonist for RAR-alpha.
    Cancer Lett, 219(1): 27-31. [Abstract] [Full-text]
66. Crosstalk between cancer cells and bone microenvironment in bone metastasis.
    Biochem Biophys Res Commun, 328(3): 679-87. [Abstract] [Full-text]
67. Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence 2.
    Biochem Biophys Res Commun, 328(2): 393-8. [Abstract] [Full-text]
68. Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma.
    Histopathology, 46(2): 153-7. [Abstract] [Full-text]
69. Her2 genotype and breast cancer progression in Korean women.
    Pathol Int, 55(2): 48-52. [Abstract] [Full-text]
70. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.
    Hum Mol Genet, 14(4): 555-63. [Abstract] [Full-text]
71. ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line.
    J Biol Chem, 280(5): 3185-96. [Abstract] [Full-text]
72. Evidence for immune defects in breast and lung cancer patients.
    Cancer Immunol Immunother, 53(12): 1146-52. [Abstract] [Full-text]
73. Juvenile papillomatosis (JP) of the female breast (Swiss Cheese Disease) -- role of breast ultrasonography.
    Ultraschall Med, 26(1): 42-5. [Abstract] [Full-text]
74. Antigen binding of human IgG Fabs mediate ERK-associated proliferation of human breast cancer cells.
    DNA Cell Biol, 24(2): 73-84. [Abstract] [Full-text]
75. A training simulator for sentinel node biopsy in breast cancer: a new standard.
    Eur J Surg Oncol, 31(2): 134-40. [Abstract] [Full-text]
76. Prognostic value of mitotic counts in axillary node negative breast cancer patients with predominantly well-differentiated tumours.
    Eur J Surg Oncol, 31(2): 128-33. [Abstract] [Full-text]
77. Sentinel node biopsy can replace four-node-sampling in staging early breast cancer.
    Eur J Surg Oncol, 31(2): 122-7. [Abstract] [Full-text]
78. Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089.
    J Steroid Biochem Mol Biol, 92(5): 365-74. [Abstract] [Full-text]
79. Experiences and resources of breast cancer patients in short-stay surgery.
    Eur J Cancer Care (Engl), 14(1): 43-52. [Abstract] [Full-text]
80. MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells in three-dimensional culture.
    J Exp Med, 201(3): 431-9. [Abstract] [Full-text]
81. Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1.
    J Clin Endocrinol Metab, 90(2): 1181-8. [Abstract] [Full-text]
82. Evaluation of HDR interstitial breast implants planned by conventional and optimized CT-based dosimetry systems with respect to dose homogeneity and conformality.
    Strahlenther Onkol, 181(2): 89-96. [Abstract] [Full-text]
83. Automatic generation of a plan optimization volume for tangential field breast cancer radiation therapy.
    Strahlenther Onkol, 181(2): 82-8. [Abstract] [Full-text]
84. Neutron versus photon radiotherapy for local control in inoperable breast cancer.
    Strahlenther Onkol, 181(2): 77-81. [Abstract] [Full-text]
85. The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer.
    Br J Cancer, 92(1): 47-54. [Abstract] [Full-text]
86. Comparison of mammography radiation dose values obtained from direct incident air kerma measurements with values from measured X-ray spectral data.
    Appl Radiat Isot, 62(4): 551-60. [Abstract] [Full-text]
87. Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.
    Br J Cancer, 92(3): 475-9. [Abstract] [Full-text]
88. 17beta-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer.
    Br J Cancer, 92(3): 547-52. [Abstract] [Full-text]
89. Association of the NuMA region on chromosome 11q13 with breast cancer susceptibility.
    Proc Natl Acad Sci U S A, 102(6): 2004-9. [Abstract] [Full-text]
90. What should the detection rates of cancers be in breast screening programmes?
    Br J Cancer, 92(3): 597-600. [Abstract] [Full-text]
91. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.
    Br J Cancer, 92(3): 467-74. [Abstract] [Full-text]
92. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer.
    Br J Cancer, 92(3): 553-61. [Abstract] [Full-text]
93. Multicolour-banding fluorescence in situ hybridisation (mbanding-FISH) to identify recurrent chromosomal alterations in breast tumour cell lines.
    Br J Cancer, 92(2): 382-8. [Abstract] [Full-text]
94. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome.
    Br J Cancer, 92(2): 225-30. [Abstract] [Full-text]
95. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells.
    Br J Cancer, 92(2): 328-33. [Abstract] [Full-text]
96. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.
    Br J Cancer, 92(2): 342-9. [Abstract] [Full-text]
97. Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study.
    Br J Cancer, 92(2): 350-8. [Abstract] [Full-text]
98. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.
    Br J Cancer, 92(1): 147-55. [Abstract] [Full-text]
99. Case-mix fails to explain variation in mastectomy rates: management of screen-detected breast cancer in a UK region 1997-2003.
    Br J Cancer, 92(1): 55-9. [Abstract] [Full-text]
100. Ultrasound-guided large-core needle biopsies of breast lesions: analysis of 962 cases to determine the number of samples for reliable tumour classification.
     Br J Cancer, 92(2): 231-5. [Abstract] [Full-text]
101. Use of antibiotics and risk of breast cancer: a population-based case-control study.
     Br J Cancer, 92(3): 594-6. [Abstract] [Full-text]
102. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.
     Br J Cancer, 92(1): 120-4. [Abstract] [Full-text]
103. Screen-detected vs clinical breast cancer: the advantage in the relative risk of lymph node metastases decreases with increasing tumour size.
     Br J Cancer, 92(1): 156-61. [Abstract] [Full-text]
104. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects.
     Br J Cancer, 92(1): 167-75. [Abstract] [Full-text]
105. Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening.
     Br J Cancer, 92(1): 162-6. [Abstract] [Full-text]
106. Characterisation of breast fine-needle aspiration biopsies by centrosome aberrations and genomic instability.
     Br J Cancer, 92(2): 389-95. [Abstract] [Full-text]
107. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen.
     Mod Pathol, 18(2): 250-9. [Abstract] [Full-text]
108. Role of radiation therapy in patients with a diagnosis of both systemic lupus erythematosus and cancer.
     Arthritis Rheum, 53(1): 67-72. [Abstract] [Full-text]
109. Initial diagnosis of breast cancer via cytological examination of a pleural effusion: a rare event facilitated by recognition of an unusual morphological pattern.
     Diagn Cytopathol, 32(3): 177-81. [Abstract] [Full-text]
110. Two somatic biallelic lesions within and near SMAD4 in a human breast cancer cell line.
     Genes Chromosomes Cancer, 42(4): 372-83. [Abstract] [Full-text]
111. Management strategies for patients with nipple discharge.
     Langenbecks Arch Surg, 390(1): 52-8. [Abstract] [Full-text]
112. Finding differentially expressed genes for pattern generation.
     Bioinformatics, 21(4): 445-50. [Abstract] [Full-text]
113. Identification of novel RARbeta2 transcript variants with short 5'-UTRs in normal and cancerous breast epithelial cells.
     Oncogene, 24(7): 1296-301. [Abstract] [Full-text]
114. Likelihood of malignancy in breast lesions characterised by ultrasound with a combined diagnostic score.
     Ultrasound Med Biol, 31(2): 179-84. [Abstract] [Full-text]
115. Ultrasound morphology of invasive lobular breast cancer is different compared with other types of breast cancer.
     Ultrasound Med Biol, 31(2): 167-74. [Abstract] [Full-text]
116. Hybrid IMRT plans--concurrently treating conventional and IMRT beams for improved breast irradiation and reduced planning time.
     Int J Radiat Oncol Biol Phys, 61(3): 922-32. [Abstract] [Full-text]
117. Choosing observers for evaluation of aesthetic results in breast cancer conservative treatment.
     Int J Radiat Oncol Biol Phys, 61(3): 879-81. [Abstract] [Full-text]
118. The pattern of lymphatic metastasis of breast cancer and its influence on the delineation of radiation fields.
     Int J Radiat Oncol Biol Phys, 61(3): 874-8. [Abstract] [Full-text]
119. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells.
     Cell, 120(3): 303-13. [Abstract] [Full-text]
120. Liver metastases from breast cancer: management of patients with significant liver dysfunction.
     Cancer Treat Rev, 31(1): 35-48. [Abstract] [Full-text]
121. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
     Cancer Treat Rev, 31(1): 1-17. [Abstract] [Full-text]
122. CD44 cross-linking induces integrin-mediated adhesion and transendothelial migration in breast cancer cell line by up-regulation of LFA-1 (alpha L beta2) and VLA-4 (alpha4beta1).
     Exp Cell Res, 304(1): 116-26. [Abstract] [Full-text]
123. Two mechanisms of caspase 9 processing in double-stranded RNA- and virus-triggered apoptosis.
     Apoptosis, 10(1): 153-66. [Abstract] [Full-text]
124. Role of p53 and reactive oxygen species in apoptotic response to copper and zinc in epithelial breast cancer cells.
     Apoptosis, 10(1): 111-21. [Abstract] [Full-text]
125. Women with disabilities: general practitioners and breast cancer screening.
     Am J Prev Med, 28(2): 215-20. [Abstract] [Full-text]
126. Primary chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil in operable breast carcinoma.
     Cancer, 103(4): 657-63. [Abstract] [Full-text]
127. Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance?
     Cancer, 103(4): 664-71. [Abstract] [Full-text]
128. Breast conservation after neoadjuvant chemotherapy.
     Cancer, 103(4): 689-95. [Abstract] [Full-text]
129. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma.
     Cancer, 103(4): 672-9. [Abstract] [Full-text]
130. Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
     Cancer, 103(4): 680-8. [Abstract] [Full-text]
131. Mammaglobin a in breast cancer: existence of multiple molecular forms.
     Int J Cancer, 114(4): 623-7. [Abstract] [Full-text]
132. NAT2 slow acetylator genotype as an important modifier of breast cancer risk.
     Int J Cancer, 114(4): 579-84. [Abstract] [Full-text]
133. Dietary carbohydrates and breast cancer risk: a prospective study of the roles of overall glycemic index and glycemic load.
     Int J Cancer, 114(4): 653-8. [Abstract] [Full-text]
134. Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer.
     Int J Cancer, 114(4): 628-33. [Abstract] [Full-text]
135. p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma.
     Int J Cancer, 114(3): 414-21. [Abstract] [Full-text]
136. NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia.
     Int J Cancer, 114(4): 585-9. [Abstract] [Full-text]
137. Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13.
     Int J Cancer, 114(4): 544-54. [Abstract] [Full-text]
138. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.
     Int J Cancer, 114(3): 448-54. [Abstract] [Full-text]
139. Size at birth and risk of breast cancer: prospective population-based study.
     Int J Cancer, 114(3): 461-4. [Abstract] [Full-text]
140. Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells.
     Int J Cancer, 114(3): 484-9. [Abstract] [Full-text]
141. Follow-up in breast cancer clinics: reassuring for patients rather than detecting recurrence.
     Psychooncology, 14(2): 94-101. [Abstract] [Full-text]
142. Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector?
     J Natl Cancer Inst, 97(4): 257-64. [Abstract] [Full-text]
143. Spatially distinct binding of Cdc42 to PAK1 and N-WASP in breast carcinoma cells.
     Mol Cell Biol, 25(5): 1680-95. [Abstract] [Full-text]
144. Comparison of three cytotoxicity tests in the evaluation of the cytotoxicity of a spermine analogue on human breast cancer cell lines.
     Toxicol In Vitro, 19(3): 379-87. [Abstract] [Full-text]
145. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells.
     Cancer Gene Ther, 12(3): 304-12. [Abstract] [Full-text]
146. Multiphoton-FLIM quantification of the EGFP-mRFP1 FRET pair for localization of membrane receptor-kinase interactions.
     Biophys J, 88(2): 1224-37. [Abstract] [Full-text]
147. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
     Oncogene, 24(8): 1477-80. [Abstract] [Full-text]
148. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells.
     Oncogene, 24(8): 1434-44. [Abstract] [Full-text]
149. Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines.
     Oncogene, 24(8): 1385-95. [Abstract] [Full-text]
150. Accuracy of intraoperative imprint cytology for sentinel lymph node evaluation in the treatment of breast carcinoma.
     Cancer, 105(1): 13-20. [Abstract] [Full-text]
151. Cytologic features of ductal carcinoma in situ in fine-needle aspiration of the breast mirror the histopathologic growth pattern heterogeneity and grading.
     Cancer, 105(1): 21-7. [Abstract] [Full-text]
152. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling.
     Oncogene, 24(8): 1338-47. [Abstract] [Full-text]
153. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death.
     Mod Pathol, 18(3): 374-81. [Abstract] [Full-text]
154. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype.
     Mod Pathol, 18(3): 398-405. [Abstract] [Full-text]
155. Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer.
     Mod Pathol, 18(3): 431-8. [Abstract] [Full-text]
156. Intramedullary spinal cord metastases in breast cancer: report of four cases and review of the literature.
     J Neurooncol, 71(1): 67-72. [Abstract] [Full-text]
157. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
     J Neurooncol, 71(1): 61-5. [Abstract] [Full-text]
158. Does a history of childhood sexual abuse affect sexual outcomes in breast cancer survivors?
     J Clin Oncol, 23(6): 1261-9. [Abstract] [Full-text]
159. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
     J Clin Oncol, 23(6): 1178-84. [Abstract] [Full-text]
160. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.
     J Clin Oncol, 23(6): 1169-77. [Abstract] [Full-text]
161. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
     J Clin Oncol, 23(6): 1161-8. [Abstract] [Full-text]
162. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
     J Clin Oncol, 23(6): 1152-60. [Abstract] [Full-text]
163. Effects of coping information and value affirmation on responses to a perceived health threat.
     Health Commun, 17(2): 133-47. [Abstract] [Full-text]
164. PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas.
     Genomics, 85(3): 338-51. [Abstract] [Full-text]
165. Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer.
     Mol Cell Proteomics, 4(2): 156-68. [Abstract] [Full-text]
166. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
     Lancet, 365(9460): 671-9. [Abstract] [Full-text]
167. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
     Gynecol Oncol, 96(3): 824-9. [Abstract] [Full-text]
168. Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness.
     Biochem Biophys Res Commun, 329(1): 318-23. [Abstract] [Full-text]
169. Selective cytotoxicity of ascochlorin in ER-negative human breast cancer cell lines.
     Biochem Biophys Res Commun, 329(1): 46-50. [Abstract] [Full-text]
170. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer.
     Am J Surg, 189(2): 236-9. [Abstract] [Full-text]
171. Locally recurrent breast cancer after conservation therapy.
     Am J Surg, 189(2): 229-35. [Abstract] [Full-text]
172. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy.
     Neoplasia, 6(6): 831-7. [Abstract] [Full-text]
173. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells.
     Neoplasia, 6(6): 786-95. [Abstract] [Full-text]
174. Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast.
     Histopathology, 46(3): 320-7. [Abstract] [Full-text]
175. Induction of cytotoxicity, aldehydic DNA lesions, and poly(ADP-ribose) polymerase-1 activation by catechol derivatives of pentachlorophenol in calf thymus DNA and in human breast cancer cells.
     Chem Res Toxicol, 18(2): 257-64. [Abstract] [Full-text]
176. Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides.
     Chem Res Toxicol, 18(2): 174-82. [Abstract] [Full-text]
177. Methyl mercury influences growth-related signaling in MCF-7 breast cancer cells.
     Environ Toxicol, 20(1): 32-44. [Abstract] [Full-text]
178. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.
     Ann Oncol, 16(3): 389-96. [Abstract] [Full-text]
179. Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy.
     Ann Oncol, 16(3): 372-82. [Abstract] [Full-text]
180. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy.
     Ann Oncol, 16(3): 383-8. [Abstract] [Full-text]
181. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
     Ann Oncol, 16(3): 359-71. [Abstract] [Full-text]
182. Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene.
     Cancer Chemother Pharmacol, 55(4): 343-6. [Abstract] [Full-text]
183. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.
     J Biol Chem, 280(8): 6742-51. [Abstract] [Full-text]
184. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.
     J Mol Med, 83(2): 132-9. [Abstract] [Full-text]
185. Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease.
     Arch Surg, 140(2): 196-8; discussion 199-200. [Abstract] [Full-text]
186. Effect of core-needle biopsy vs fine-needle aspiration on pathologic measurement of tumor size in breast cancer.
     Arch Surg, 140(2): 125-8. [Abstract] [Full-text]
187. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
     Am J Med Genet A, 133(2): 165-9. [Abstract] [Full-text]
188. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer.
     Semin Oncol, 31(6): 3-9. [Abstract] [Full-text]
189. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.
     Semin Oncol, 31(6): 25-33. [Abstract] [Full-text]
190. Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy--a longitudinal study.
     Br J Cancer, 92(4): 673-80. [Abstract] [Full-text]
191. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group.
     Br J Cancer, 92(4): 639-44. [Abstract] [Full-text]
192. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome.
     Mutat Res, 581(1): 153-63. [Abstract] [Full-text]
193. Are there downsides to mammography screening?
     Breast J, 11: S7-10. [Abstract] [Full-text]
194. Targeted therapies in breast cancer.
     Breast J, 11: S30-5. [Abstract] [Full-text]
195. Screening mammography controversies: resolved, partly resolved, and unresolved.
     Breast J, 11: S3-6. [Abstract] [Full-text]
196. Applying innovations in surgical and radiation oncology to breast conservation therapy.
     Breast J, 11: S24-9. [Abstract] [Full-text]
197. Integrate, innovate, imitate: surviving and thriving in the world of breast cancer economics.
     Breast J, 11: S20-3. [Abstract] [Full-text]
198. Risk assessment: controversies and management of moderate- to high-risk individuals.
     Breast J, 11: S11-9. [Abstract] [Full-text]
199. In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways.
     J Pathol, 205(4): 530-6. [Abstract] [Full-text]
200. Genomic approaches in the management and treatment of breast cancer.
     Br J Cancer, 92(4): 618-24. [Abstract] [Full-text]
201. Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals.
     Br J Cancer, 92(4): 784-90. [Abstract] [Full-text]
202. Does deprivation affect breast cancer management?
     Br J Cancer, 92(4): 631-3. [Abstract] [Full-text]
203. Aspects of molecular phenotype and its correlations with breast cancer behaviour and taxonomy.
     Br J Cancer, 92(4): 613-7. [Abstract] [Full-text]
204. Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines.
     Br J Cancer, 92(4): 634-8. [Abstract] [Full-text]
205. Fiberoptic ductoscopy findings in women with and without spontaneous nipple discharge.
     Cancer, 103(5): 914-21. [Abstract] [Full-text]
206. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.
     Cancer, 103(5): 884-91. [Abstract] [Full-text]
207. Role of community risk factors and resources on breast carcinoma stage at diagnosis.
     Cancer, 103(5): 922-30. [Abstract] [Full-text]
208. Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma.
     Cancer, 103(5): 906-13. [Abstract] [Full-text]
209. Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF.
     Gene Ther, 12(5): 452-60. [Abstract] [Full-text]
210. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
     Cancer, 103(5): 900-5. [Abstract] [Full-text]
211. Predictors of breast conservation therapy: size is not all that matters.
     Cancer, 103(5): 892-9. [Abstract] [Full-text]
212. Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration.
     J Neurol, 252(2): 197-201. [Abstract] [Full-text]
213. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
     JAMA, 293(8): 964-9. [Abstract] [Full-text]
214. Osteogenic pulmonary metastases originating from a phyllodes tumour of the breast with osteosarcomatous differentiation.
     Australas Radiol, 49(1): 63-5. [Abstract] [Full-text]
215. Changes in practice of breast cancer radiotherapy 1998-2002: an Australasian survey.
     Australas Radiol, 49(1): 44-52. [Abstract] [Full-text]
216. Absence of adverse early quality of life outcomes of radiation therapy in breast conservation therapy for early breast cancer.
     Australas Radiol, 49(1): 39-43. [Abstract] [Full-text]
217. Predictors of a positive baseline bone scan in breast cancer.
     Australas Radiol, 49(1): 21-6. [Abstract] [Full-text]
218. Shutter-speed analysis of contrast reagent bolus-tracking data: Preliminary observations in benign and malignant breast disease.
     Magn Reson Med, 53(3): 724-9. [Abstract] [Full-text]
219. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
     Oncogene, 24(9): 1648-52. [Abstract] [Full-text]
220. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
     Oncogene, 24(9): 1625-33. [Abstract] [Full-text]
221. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells.
     Carcinogenesis, 26(3): 557-64. [Abstract] [Full-text]
222. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells.
     Int J Cancer, 114(5): 713-9. [Abstract] [Full-text]
223. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS.
     Int J Cancer, 114(5): 791-6. [Abstract] [Full-text]
224. High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry.
     Int J Cancer, 114(5): 720-9. [Abstract] [Full-text]
225. Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro.
     Oncogene, 24(9): 1525-32. [Abstract] [Full-text]
226. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.
     Carcinogenesis, 26(3): 643-7. [Abstract] [Full-text]
227. Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast.
     Breast J, 11(2): 140-2. [Abstract] [Full-text]
228. Breast cancer pseudometastasis in a sentinel lymph node with cytokeratin-positive debris.
     Breast J, 11(2): 134-7. [Abstract] [Full-text]
229. Excision only for tubular carcinoma of the breast.
     Breast J, 11(2): 129-33. [Abstract] [Full-text]
230. Race is a fundamental prognostic indicator for 2325 northeastern Ohio women with infiltrating breast cancer.
     Breast J, 11(2): 124-8. [Abstract] [Full-text]
231. Risk of angiosarcoma following breast conservation: a clinical alert.
     Breast J, 11(2): 115-23. [Abstract] [Full-text]
232. Implementation of sentinel lymph node biopsy with blue dye outside a specialized center: can we improve quality assurance?
     Breast J, 11(2): 103-7. [Abstract] [Full-text]
233. Total mastectomy under local anesthesia: the tumescent technique.
     Breast J, 11(2): 100-2. [Abstract] [Full-text]
234. Use of complementary and alternative medicine by patients with breast cancer: observations from a health-care survey.
     Support Care Cancer, 12(11): 789-96. [Abstract] [Full-text]
235. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.
     J Neurooncol, 71(3): 295-9. [Abstract] [Full-text]
236. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
     J Clin Oncol, 23(7): 1420-30. [Abstract] [Full-text]
237. Postmastectomy radiation and mortality in women with T1-2 node-positive breast cancer.
     J Clin Oncol, 23(7): 1409-19. [Abstract] [Full-text]
238. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
     J Clin Oncol, 23(7): 1401-8. [Abstract] [Full-text]
239. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
     J Clin Oncol, 23(7): 1390-400. [Abstract] [Full-text]
240. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement.
     J Clin Oncol, 23(7): 1379-89. [Abstract] [Full-text]
241. One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer.
     Cancer Res, 65(4): 1606-14. [Abstract] [Full-text]
242. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
     Cancer Res, 65(4): 1541-6. [Abstract] [Full-text]
243. Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells.
     Cancer Res, 65(4): 1433-41. [Abstract] [Full-text]
244. Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging.
     Cancer Res, 65(4): 1425-32. [Abstract] [Full-text]
245. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.
     Cancer Res, 65(4): 1384-93. [Abstract] [Full-text]
246. Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas.
     Cancer Res, 65(4): 1376-83. [Abstract] [Full-text]
247. Altered gene expression patterns in MCF-7 cells induced by the urban dust particulate complex mixture standard reference material 1649a.
     Cancer Res, 65(4): 1251-8. [Abstract] [Full-text]
248. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.
     Cancer Res, 65(4): 1141-5. [Abstract] [Full-text]
249. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations.
     Cancer Epidemiol Biomarkers Prev, 14(2): 529-32. [Abstract] [Full-text]
250. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
     Cancer Epidemiol Biomarkers Prev, 14(2): 350-6. [Abstract] [Full-text]
251. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer.
     Cancer Epidemiol Biomarkers Prev, 14(2): 343-9. [Abstract] [Full-text]
252. Polymorphisms in XRCC1 modify the association between polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, dietary antioxidants, and breast cancer risk.
     Cancer Epidemiol Biomarkers Prev, 14(2): 336-42. [Abstract] [Full-text]
253. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the shanghai breast cancer study and a meta-analysis.
     Cancer Epidemiol Biomarkers Prev, 14(2): 329-35. [Abstract] [Full-text]
254. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population.
     Cancer Epidemiol Biomarkers Prev, 14(2): 324-8. [Abstract] [Full-text]
255. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer.
     Cancer Epidemiol Biomarkers Prev, 14(2): 319-23. [Abstract] [Full-text]
256. Breast cancer yield for screening mammographic examinations with recommendation for short-interval follow-up.
     Radiology, 234(3): 684-92. [Abstract] [Full-text]
257. Measurements and treatment planning calculations of electron dose distributions below bolus edges.
     Radiother Oncol, 74(2): 217-20. [Abstract] [Full-text]
258. MRI findings of gastric metastases from breast carcinoma.
     Magn Reson Imaging, 23(1): 115-8. [Abstract] [Full-text]
259. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
     Clin Genet, 67(4): 322-9. [Abstract] [Full-text]
260. Immunoreactive estrogen receptor in breast tumor and adjacent tissue: association with clinicopathological characteristics in Indian population.
     J Surg Oncol, 89(4): 251-5. [Abstract] [Full-text]
261. Weight, weight gain, and survival after breast cancer diagnosis.
     J Clin Oncol, 23(7): 1370-8. [Abstract] [Full-text]
262. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
     Cytometry B Clin Cytom, 64(1): 43-52. [Abstract] [Full-text]
263. Stability of the HER2 gene after primary chemotherapy in advanced breast cancer.
     Virchows Arch, 446(2): 136-41. [Abstract] [Full-text]
264. Clinically and mammographically occult breast lesions on MR images: potential effect of computerized assessment on clinical reading.
     Radiology, 234(3): 693-701. [Abstract] [Full-text]
265. Carcinoma ex-pleomorphic adenoma of the breast. Report of three cases suggesting a relationship to metaplastic carcinoma of matrix-producing type.
     Virchows Arch, 446(2): 142-9. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.